Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 763-769

  Hill, Brian T ^a   Sweetenham, John ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

activated B cell; Diffuse large B cell lymphoma; germinal center; molecular subtype

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB;

ADJUVANT THERAPY; ALGORITHM; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL FEATURE; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; REVIEW; SALVAGE THERAPY; TUMOR CLASSIFICATION;

GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84859993680     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.626882     Document Type: Review

References (54)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diff use large B-cell lymphoma identifi ed by gene expression profi ling. Nature 2000;403:503-511. (Pubitemid 30082188)
2. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profi ling to predict survival after chemotherapy for diff use large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947. (Pubitemid 34651353)
3. Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diff use large B-cell lymphomas. Blood 2000;95:1797-1803. (Pubitemid 30120845)
4. Lossos IS, Alizadeh AA, Eisen MB, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diff use large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209-10213.
5. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diff use large B cell lymphoma cells. J Exp Med 2001;194:1861-1874. (Pubitemid 34028664)
6. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-2707. (Pubitemid 46482061)
7. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diff use large B-cell lymphoma. Nature 2010;463:88-92.
8. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-716.
9. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diff use large B cell lymphoma. Science 2008;319:1676-1679. (Pubitemid 351432507)
10. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-119.
11. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confi rmation of the molecular classifi cation of diff use large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282. (Pubitemid 38029949)
13. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifi es diff use large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
14. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diff use large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-207.
15. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profi ling based on Bcl-2, CD10 and MUM1 expression improves risk stratifi cation in patients with primary nodal diff use large B cell lymphoma. J Pathol 2006;208:714-723.
16. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene expression profi ling and not immunophenotypic algorithms predicts prognosis in patients with diff use large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836-4843.
17. Rayman N, Lam KH, van der Holt B, et al. Prognostic relevance of immunohistochemical subclassifi cation of diff use large B-cell lymphoma in two prospective phase III clinical trials. Clin Lymphoma Myeloma Leuk 2011;11:23-32.
18. d e Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diff use large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications-A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-812. (Pubitemid 350002880)
19. d e Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diff use large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128-138.
20. Rimsza LM, Wright GW, Schwartz M, et al. Classifi cation of diff use large B cell lymphoma into germinal center and activated B cell subtypes using a nuclease protection assay on paraffi n embedded tissues. Clin Cancer Res 2011;17:3727-3732.
21. Shaknovich R, Geng H, Johnson NA, et al. DNA methylation signatures defi ne molecular subtypes of diff use large B-cell lymphoma. Blood 2010;116:e81-e89.
22. Montes-Moreno S, Martinez N, Sanchez-Espiridion B, et al. MicroRNA expression in diff use large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011;118:1034-1040.
23. Jardin F, Jais JP, Molina TJ, et al. Diff use large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: A GELA study. Blood 2010;116:1092-1104.
24. van Galen JC, Muris JJ, Giroth CP, et al. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diff use large B-cell lymphomas. Histopathology 2008;52:578-584. (Pubitemid 351442651)
25. van Galen JC, Muris JJ, Oudejans JJ, et al. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 2007;60:167-172.
26. L i D, Xie P, Mi C. Primary testicular diff use large B-cell lymphoma shows an activated B-cell-like phenotype. Pathol Res Pract 2010;206:611-615.
27. A l-Abbadi MA, Hattab EM, Tarawneh MS, et al. Primary testicular diff use large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases. Mod Pathol 2006;19:1521-1527. (Pubitemid 44789919)
28. Carbone A. Primary diff use large B-cell lymphoma of the breast: An aggressive subgroup with nongerminal center B-cell-like phenotype. Am J Hematol 2009;84:129-130.
29. Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diff use large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 2005;18:398-405. (Pubitemid 40395359)
30. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063-1069. (Pubitemid 36329149)
31. Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases. Blood 2006;107:190-196. (Pubitemid 43053543)
32. Lin CH, Kuo KT, Chuang SS, et al. Comparison of the expression and prognostic signifi cance of diff erentiation markers between diff use large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006;12:1152-1156.
33. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identifi ed by gene expression profi ling. Blood 2005;105:3671-3678. (Pubitemid 40628215)
34. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: A harbinger of eventual transformation to diff use aggressive lymphoma. Blood 2003;102:1443-1448. (Pubitemid 36988055)
35. Lossos IS, Levy R. Mutation analysis of the 5'noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: Evidence for recurrent mutations and intraclonal heterogeneity. Blood 2000;95:1400-1405. (Pubitemid 30099853)
36. Davies AJ, Rosenwald A, Wright G, et al. Transformation of follicular lymphoma to diff use large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007;136:286-293. (Pubitemid 46020756)
37. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diff use large B-cell lymphoma. Blood 1998;92:3152-3162. (Pubitemid 28492322)
38. Ladanyi M, Offi t K, Jhanwar SC, et al. MYC rearrangement and translocations involving band 8q24 in diff use large cell lymphomas. Blood 1991;77:1057-1063.
39. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations aff ecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diff use large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226-2229.
40. Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diff use large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777-783.
41. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diff use large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537.
42. Xicoy B, Ribera JM, Mate JL, et al. Immunohistochemical expression profi le and prognosis in patients with diff use large B-cell lymphoma with or without human immunodefi ciency virus infection. Leuk Lymphoma 2010;51:2063-2069.
43. Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diff use large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 2009;27:5039-5048.
44. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-Associated diff use large B-cell lymphoma. Blood 2010;115:3017-3024.
45. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
46. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-Associated proteins and chromosomal breakpoints in poor-risk diff use large B-cell lymphoma. J Clin Oncol 2006;24:4135-4142. (Pubitemid 46622290)
47. Zinzani PL, Broccoli A, Stefoni V, et al. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diff use large B-cell lymphoma patients. Cancer 2010;116:5667-5675.
48. Costa LJ, Feldman AL, Micallef IN, et al. Germinal center B (GCB) and non-GCB cell-like diff use large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008;142:404-412. (Pubitemid 351962182)
49. Hallack Neto AE, Dulley FL, Coelho Siqueira SA, et al. Prognostic impact of diff use large B-cell lymphoma subgroups in patients undergoing autologous SCT. Bone Marrow Transplant 2009;43: 323-325.
50. Nyman H, Jantunen E, Juvonen E, et al. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diff use large B-cell lymphoma. Bone Marrow Transplant 2008;42:93-98.
51. Moskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383-3385. (Pubitemid 41609171)
52. Dunleavy K, Pittaluga S, Czuczman MS, et al. Diff erential effi cacy of bortezomib plus chemotherapy within molecular subtypes of diff use large B-cell lymphoma. Blood 2009;113:6069-6076.
53. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diff use large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.
54. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diff use large b-cell lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype. Cancer 2011 Apr 14.